<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    April 29, 2021

    CDD Wins $120,000 Prize in Competitive NCATS ASPIRE Challenge #2

     

    CDD Press Release Logo

    Biotech-in-a-Box, CDD's Solution for Combating the Opioid Crisis

    Burlingame, California - April 24, 2021 - Collaborative Drug Discovery, Inc. (CDD) won $120,000 in the 2nd competitive stage of an NCATS ASPIRE Challenge hosted by the National Institutes of Health. In Oct 2019, CDD won $100,000 in the 1st competitive stage. For this challenge CDD designed a unique screening program that NCATS can use in its own facilities and pass on to others for combating the opioid crisis, accelerating the identification of less addictive and safer analgesics.

    The official announcement mentioning CDD with collaborators Christopher Lipinski and Lawrence Callahan (FDA), along with the other prize winners is available on this NIH web page.

    About Collaborative Drug Discovery, Inc.

    CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.



    Tag(s): CDD Blog , News

    Other posts you might be interested in

    View All Posts
    CDD Vault Snack
    4 min   April 15, 2024
    Vault Snack #23 – New Interface for Creating Protocol Readout Definitions
    Read More
    CDD Blog
    9 min   March 26, 2024
    Drug Discovery Industry Roundup with Barry Bunin — March 26, 2024
    Read More
    CDD Blog
    2 min   March 26, 2024
    Recorded Webinar: Trends & Better Practices for the Use of Gen AI & LLMs
    Read More